Solid Biosciences Inc. (SLDB) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Solid Biosciences reported revenue of $0. Net income was -$174.3M, or -$1.99 per diluted share. Operating activities generated -$156.3M of cash, leaving -$157.5M of free cash flow. At fiscal year end, Solid Biosciences held $232.5M in total assets against $52.5M in total liabilities, including $59.9M of cash and equivalents.
Open the full interactive Solid Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Solid Biosciences Key Stats
| Share Price | $5.82 |
|---|---|
| Market Cap | $836.3M |
| 52-Week Range | $3.93 – $11.15 |
| Shares Outstanding | 143.7 million (basic, 2026 Q2) |
Solid Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $13.6M | $8.1M | $0 | $0 | $0 |
| Operating Income | -$88.4M | -$72.3M | -$106.5M | -$104.3M | -$129.7M | -$179.2M |
| Pre-Tax Income | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$124.7M | -$174.2M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$124.7M | -$174.3M |
| Diluted EPS | -$25.50 | -$10.20 | -$10.10 | -$4.83 | -$3.06 | -$1.99 |
Solid Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$45.8M | -$49.8M | -$56.7M | -$54.8M |
| Diluted EPS | -$0.48 | -$0.57 | -$0.52 | -$0.38 |
Solid Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $154.7M | $119.1M | $155.4M | $74.0M | $80.2M | $59.9M |
| Current Assets | $158.9M | $222.6M | $219.6M | $129.7M | $157.3M | $205.5M |
| Total Assets | $171.2M | $232.4M | $260.3M | $164.9M | $188.7M | $232.5M |
| Current Liabilities | $24.5M | $23.6M | $22.5M | $14.5M | $30.3M | $33.5M |
| Total Liabilities | $39.1M | $24.2M | $48.6M | $38.5M | $51.4M | $52.5M |
| Shareholders' Equity | $132.1M | $208.2M | $211.7M | $126.5M | $137.2M | $180.0M |
Solid Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$56.6M | -$77.8M | -$98.0M | -$94.2M | -$100.0M | -$156.3M |
| Cash From Investing | $6.6M | -$91.1M | $59.2M | $9.7M | -$16.1M | -$58.5M |
| Cash From Financing | $128.7M | $135.0M | $74.8M | $3.1M | $122.4M | $194.4M |
| Free Cash Flow | -$57.5M | -$79.0M | -$101.0M | -$95.7M | -$100.7M | -$157.5M |
Figures from Solid Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Solid Biosciences financials page for every line item.
Solid Biosciences Company Profile
| Ticker | SLDB |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Charlestown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001707502 |
Frequently Asked Questions
What was Solid Biosciences' revenue in fiscal 2025?
Solid Biosciences (SLDB) reported revenue of $0 for fiscal 2025.
What is Solid Biosciences' annual revenue history?
Solid Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $13.6M; 2022: $8.1M; 2023: $0; 2024: $0; 2025: $0.
What was Solid Biosciences' net income in fiscal 2025?
Solid Biosciences reported net income of -$174.3M for fiscal 2025.
What was Solid Biosciences' earnings per share (EPS) in fiscal 2025?
Solid Biosciences' diluted EPS was -$1.99 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Solid Biosciences generate in fiscal 2025?
Solid Biosciences generated -$157.5M of free cash flow in fiscal 2025.
What was Solid Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Solid Biosciences reported revenue of $0.
How many shares of Solid Biosciences are outstanding?
Solid Biosciences reported a weighted average of 143.7 million basic shares outstanding in 2026 Q2.
What is Solid Biosciences' market cap?
Based on its latest closing price, Solid Biosciences (SLDB) has a market capitalization of about $836.3M.
When does Solid Biosciences' fiscal year end?
Solid Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Solid Biosciences headquartered?
Solid Biosciences lists its business address in Charlestown, Massachusetts in its SEC filings.
Solid Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →